Sara Nik
Stock Analyst at H.C. Wainwright
(0.07)
# 4,729
Out of 5,020 analysts
58
Total ratings
13.2%
Success rate
-26.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBRX Moleculin Biotech | Reiterated: Buy | $3 | $0.5038 | +495.47% | 20 | Sep 29, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.4891 | +513.37% | 11 | Sep 21, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 12.00 | kr 1.46 | +721.36% | 11 | Sep 21, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $9 | $1.24 | +625.81% | 5 | Aug 21, 2026 | |
| CRIS Curis | Reiterated: Buy | $43 | $0.8307 | +5,076.36% | 10 | Aug 17, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $1.56 | n/a | 1 | Aug 13, 2025 |
Moleculin Biotech
Sep 29, 2026
Reiterated: Buy
Price Target: $3
Current: $0.5038
Upside: +495.47%
Pasithea Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $3
Current: $0.4891
Upside: +513.37%
Cantargia AB (publ)
Sep 21, 2026
Reiterated: Buy
Price Target: kr 12.00
Current: kr 1.46
Upside: +721.36%
Tvardi Therapeutics
Aug 21, 2026
Reiterated: Buy
Price Target: $9
Current: $1.24
Upside: +625.81%
Curis
Aug 17, 2026
Reiterated: Buy
Price Target: $43
Current: $0.8307
Upside: +5,076.36%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $1.56
Upside: n/a